Necrotizing Fasciitis Market Emerging Trends, Size, Share and Growth Analysis by 2027

Market Scenario:

Also known as flesh-eating disease, necrotizing fasciitis is a rare bacterial infection affecting the tissue beneath the skin, surrounding muscles, and organs. The bacteria that is responsible for the disease releases toxins results into the damage nearby tissue. There are four major types for necrotizing fasciitis – type I known as polymicrobial infection, type II caused by haemolytic group A streptococcus, staphylococci such as methicillin resistant strains/MRSA, type III caused by bacterium such as clostridium, and others. It starts as a minor injury such as a small cut, but may get worst and can be life threatening if left untreated. Major risk factors for the disease are diabetes, cancer, obesity, intravenous drug use, alcoholism, and peripheral vascular disease. The disease can be prevented by maintaining hygiene which includes proper wound care and hand washing.

Browse Sample of the Report @  https://www.marketresearchfuture.com/sample_request/5450

 The global necrotizing fasciitis market is majorly driven by the increasing prevalence of cancer, diabetes, continuously increasing geriatric population and increasing number of patients suffering from various bacterial infection. However, the growth of the market is restricted due to lack of awareness about necrotizing fasciitis and high cost of treatment.

The global necrotizing fasciitis market is expected to grow at a CAGR of 6.2% during the forecasted period.

Segments 

• The global necrotizing fasciitis market is segmented on the basis of type, treatment, and end users.

• On the basis of the type, the market is categorized into Type I, Type II, Type III and others.

• On the basis of the treatment, the market is segmented into intravenous antibiotics, surgery, hyperbaric oxygen treatment and others.

• On the basis of the end users, the market is segmented into hospitals & clinics, surgical centers and others.

Regional Analysis

America accounts for the largest share in the global necrotizing fasciitis market owing to presence of key players in the market and rising emphasis on diagnosis and treatment of rare diseases. Furthermore, rising awareness about bacterial infection is further set to accelerate the growth of the market. North America is the accounted for the highest market share in this region with the U.S. being the largest market followed by Canada. In the U.S, the prevalence of cardiovascular disease is found to be increasing from last few years. This is attributed to the rising prevalence of chronic diseases such as obesity and diabetes which are the major risk factors for cardiovascular diseases. As per the Center for Disease Control & Prevention (CDC), in 2015, 28.4 million adults were diagnosed with cardiovascular diseases in the U.S. alone.

Europe is the second largest market and holds a noticeable share in the global necrotizing fasciitis market. The European market is expected to grow significantly during the forecast period owing to availability of advanced treatment facilities and skilled medical professionals. Furthermore, extensive research and development activities for the treatment of rare disease and increasing government support.

Asia Pacific is expected to be the fastest growing market. Increasing prevalence of chronic diseases such as diabetes, cancer and bacterial infection in developing countries is the major driver for the market growth. China and India are the fastest growing regions owing to increasing geriatric population. Also, the diabetes is one of the major chronic conditions affecting large number of patients, thereby influencing the market growth. Rising awareness about the infections and availability of new treatment methods drive the market in this region. Rising healthcare expenditure and overall growth of healthcare diagnostic and treatment industry also drive the market. According to the International Diabetic Federation, about 415 million people had diabetes across the globe in 2015, which is expected to reach 642 million by 2040. It also stated that 98.4 million and 65.1 million diabetic population lived in China and India, respectively. It stated that in 2015, 3.7% of the Asian population was diagnosed with chronic heart disease, while 21% of the population had hypertension

The Middle East & Africa is expected to show the least growth in the market due to some major factors such as lack of awareness about necrotizing fasciitis, limited access and availability of treatment facilities. In the Middle East, United Arab Emirates holds the largest market share owing to development of healthcare industry and rising availability of specialty care centers.

Key Players

Some of the key players in necrotizing fasciitis market are Merck & Co. (U.S.), WOCKHARDT (India), Atox Bio (Israel), Teva Pharmaceutical Industries (Israel), Basilea Pharmaceutica Ltd. (Switzerland), and MELINTA THERAPEUTICS, INC. (U.S.)

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/necrotizing-fasciitis-market-5450

About US:

Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact Us:

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune – 411028

Maharashtra, India

Phone: +1 646 845 9312

Email: sales@marketresearchfuture.com

Lancet and Pen Needles Market: Segmentation, Industry trends and Development to 2027

 Also known as packed-cell volume (PCV) test, hematocrit test is used to measure the percentage of Red Blood Cells (RBCs) in the blood. The major function of the RBCs is to carry blood throughout the body. The test is usually performed to diagnose various diseases such as anemia, leukemia, lymphoma, congenital heart disease, and others. The test determines the elevation in the percentage of normal RBCs which is 38.8%-50% in men and 34.9%-44.5% in women. The hematocrit test is one of the tests included under complete blood count (CBC) test.

Browse Sample of the Report @  https://www.marketresearchfuture.com/sample_request/5553

Cardiovascular diseases, cancer, and kidney diseases are increasing the economic burden of various developing and developed nations across the globe. The market for hematocrit test is driven by rising prevalence of chronic diseases such as cardiovascular diseases, diabetes, and others along with changing lifestyle, and increasing demand for diagnostic devices for cardiovascular diseases. However, limited number of trained personnel has restrained the growth of the market. However, the high cost of diagnosis and treatment of cardiovascular diseases also restrains the growth of the market. As per the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), the overall prevalence of Chronic Kidney Disease (CKD) in the general population across the globe is nearly 14%. However, the growth of the market is restrained by the inaccurate or misleading result of the test and unawareness about hematocrit test in the diagnosis of the disease.

The global hematocrit test market is expected to grow at a CAGR of 4.5% during the forecast period.

Segments                                                                                                                                          

The global hematocrit test market is segmented on the basis of product, indication, devices, and end-user.

On the basis of product, the market is segmented into the analyzer, hematocrit test meter, and others.

On the basis of indication, the market is segmented into anemia, leukemia, lymphoma, congenital heart disease, kidney tumor, and others.

On the basis of the end-user, the market is segmented into hospitals & clinics, diagnostic centers, and others.

Intended Audience

• Medical Device Manufacturers
• Medical Device Suppliers
• Medical Research Laboratories
• Research and Development (R&D) Companies
• Market Research and Consulting Service Providers
• Potential Investors

Regional Analysis of the Global Hematocrit Test Market                      

The global hematocrit test market consists of four major regions namely, the Americas, Europe, Asia Pacific and the Middle East & Africa, with the Americas capturing the largest market share. The growth of the market is attributed to an increase in the demand for diagnostic procedures, and rising importance of hematology testing for the diagnosis of various chronic diseases. North America accounts for the major share in the American hematocrit test market which is attributed to extensive use of hematocrit test with other diagnostic tests. According to the Center for the Disease Control and Prevention (CDC), as of 2012, nearly half of all the adults, 117 million population in the U.S. had one or more chronic health conditions. One in four adults were diagnosed with two or more chronic health diseases.

In Europe, the growth of the market is driven by increasing demand for diagnostic devices and instrument in hospitals and diagnostic centers. Germany, the U.K, and France are the major contributors to the growth of the market owing to an increase in the number of key players engaged in the manufacturing of medical devices and instruments and rising expenditure in research and development by these major economies. Additionally, well-developed healthcare sector, ever-increasing patient population and high healthcare expenditure by the European nations fuel the market growth.

The Asia Pacific is expecting the fastest growth in the market due to the flourishing growth of healthcare industries in developing economies such as India. Additionally, the ever-increasing prevalence of kidney diseases and cardiovascular diseases and rising demand for quality devices in the healthcare sector is expected to lead the use of advanced equipment, which, in turn, may speed up the market growth in the region. Rising geriatric population with chronic diseases further creates the economic burden on the developing nations thereby accelerating the market growth.

The Middle East & Africa hold the least share in the market. The market in this regions exhibits steady growth owing to an increase in the demand for the diagnostic and treatment services.  In the Middle East and Africa, the United Arab Emirates (UAE) hold the largest market share owing to the availability of diagnostic and treatment services. Africa shows slow growth due to low technology penetration in developing countries.

Key Players in the Global Hematocrit Test Market         

Some of the key players in this market are Abbott (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), Siemens AG (Germany), Beckman Coulter, Inc. (U.S.), Bio-Rad Laboratories, Inc. (U.S.), Horiba, Ltd. (Japan), Mindray Medical International Limited (China), Boule Diagnostics AB (Sweden), Nihon Kohden Corporation (Japan), Sysmex Corporation (Japan), and others.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/hematocrit-test-market-5553

About US:

Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact Us:

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune – 411028

Maharashtra, India

Phone: +1 646 845 9312

Email: sales@marketresearchfuture.com

Lancet and Pen Needles Market to Witness Widespread Expansion During 2020-2027

 Lancet and pen needles can be effectively used for the blood-based diagnosis, monitoring, and medication of diseases like diabetes and osteoporosis.  Pen needles are used in conjunction with the injection pens. Structurally, a pen needle consists of a hollow needle, which is embedded in a plastic hub and attaches to the injection pen. The lancet are double edged blades or needles and appears similar to the small scalpels. The market for lancet and pen needles is expected to grow at a healthy CAGR during the forecast period in the Asia Pacific region due to increasing prevalence of diseases like diabetes and osteoporosis. According to a study conducted by the American Diabetes Association in 2016, about 80% of the diabetic patients resides in the developing countries and it is estimated that the rise of type 2 diabetes in South Asia is likely to be 150% between 2000 and 2035. Moreover, in the Western Pacific region, the number of diabetic patients is expected to reach 201.8 million by 2035. Additionally, according to the International Osteoporosis Foundation by 2050, over ~50% of all osteoporotic hip fractures are expected to occur in Asia. Factors such as increasing geriatric population and growing healthcare expenditure along with favourable government policies are projected to boost the market growth during the forecast period.  However, the need to remove the pin after a single use and high cost as compared to the insulin vials may restrain the market growth during the forecast period.

 

Browse Sample of the Report @  https://www.marketresearchfuture.com/sample_request/630

The Asia Pacific lancet and pen needles market is expected to grow at an approximate CAGR of 6.5% during the forecast period, 2017-2023.

Intended Audience

• Pharmaceutical companies
• Biotechnological institutes
• Government and Private Laboratories
• Research and Development (R&D) Companies
• Medical Research Laboratories
• Market Research and Consulting Service Providers

Segmentation

The Asia Pacific lancet and pen needles market is segmented on the basis of therapy, gauge, needle length, and end users.

On the basis of the therapy, the market is segmented into insulin, glucagon-like peptide-1 (GLP-1), growth hormones, and others.

On the basis of the gauge, the market is categorized into 17/18G, 21G, 23G, and others.

On the basis of the needle length, the market is segmented into 4mm, 8mm, 12mm, and others.

On the basis of the end users, the market is segmented into hospitals & clinics, medical institutions & research organizations, and others.

 

Regional Analysis

On the regional basis, Asia Pacific is segmented into Japan, India, China, the Republic of Korea, Australia, and the Rest of Asia Pacific.

Japan holds a major share of the market followed by the Republic of Korea and Australia owing to the well-developed healthcare sector and high per capita healthcare expenditure. In 2014, according to the Statistics Bureau, Japan’s total medical care expenditure was about 11.20% of the national income, which accounted for USD 0.37 trillion. Additionally, favorable governmental policies boost the market growth in these regions.

China and India have a growing market due to huge population base, increasing demand for the better quality products, rapidly changing the economy, increasing healthcare expenditure, and rising number of pharmaceutical & biotechnological companies. Moreover, increasing number of healthcare organizations like a hospital, the private research institute has led to increasing in the market in India. Rest of Asia Pacific holds the least share of the market.

 

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/asia-pacific-lancet-pen-needels-market-630

About US:

Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact Us:

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune – 411028

Maharashtra, India

Phone: +1 646 845 9312

Email: sales@marketresearchfuture.com

Throat Lozenges Market 2020 Analysis, Industry Size, Share Leaders, Current Status by Major vendors and Trends by Forecast to 2027

 According to MRFR,   the global throat lozenges market analysis is expected to witness a moderate CAGR of 4.20% and generate a market value of USD 6.58 Billion by the end of 2023.

COVID-19 Analysis

A positive effect of the COVID-19 pandemic is expected on the Global Throat Lozenges Market. The typical signs of COVID-19 are a sore throat and coughing. Therefore, people under home confinement have been using at-home remedies for COVID-19 such as throat lozenges for chronic cough and over-the-counter pain relief for body aches. Therefore, in the next 2 to 3 years, the growing demand for throat lozenges for the treatment of initial COVID-19 symptoms of coughing and throat pain is expected to fuel the growth of the market for throat lozenges. The growing demand for throat lozenges has also led to the production of throat lozenges by companies from different industries. 

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/1212 

Throat infections are common, and lozenges are usually the first line of defence for such conditions. Throat lozenges brands continue to leverage marketing tools to increase the commercial visibility of their product.  Other factors that are linked with the growth of global throat lozenges market include the development of new ingredients, rapid product penetration in fast-developing countries and low-price of throat lozenges. However, the availability of alternative treatments and therapies somewhat inhibit the market opportunities for throat lozenges.

Global Throat Lozenges Market: Segmental Analysis

MRFR’s report include a descriptive segmental analysis of the market based on type, ingredient, and indication. By type, the market has been segmented into hard-candy lozenges, soft lozenges, and compressed lozenges.  The hard-candy segment is further sub-segmented into chewy or caramel based medicated tablets and centre filled hard-candy lozenges. The hard candy lozenges segment currently accounts for more than one-third share of the market and is expected to remain highly lucrative during the forecast period. In 2017, over USD 2400 Mn worth hard-candy lozenges were sold globally. By ingredient, the market has been segmented into menthol, eucalyptus oil, mint, peppermint oil, honey & ginger, lemon, and others. Among these, the menthol segment accounts for the largest market share. In 2017, the segment reached a market valuation in excess of USD 1700 Mn and projected to expand at a CAGR of 3.45% by 2023. By indication, the market has been segmented into cold and cough, sore throat, throat diseases, and others. The sore throat segment holds the pole position and the trend is likely to continue over 2023. The segment surpassed a market valuation of USD 2400 Mn in 2017.

Global Throat Lozenges Market: Regional Analysis  

The report also includes a regional analysis of the market that covers Europe, North America, Asia Pacific (APAC), South America and the Middle East & Africa (MEA). Currently, North America and South America collectively account for the largest market share. In 2017, the Americas accounted for more that 31% share of the market.  North America in particular is expected to remain an important market for throat lozenges during the review period. Sales of OTC medial products including throat lozenges will continue to grow in the region in the years to come. Meanwhile, Europe has emerged as the single largest market for throat lozenges. Prevalence of common cold is considerably high in various parts of Europe, which acts as favorable element for the region’s throat lozenges market.

Global Throat Lozenges Market: Competitive Landscape

Bausch Health Companies Inc, Procter & Gamble, Prestige Brands Inc, Wrigley Company, Reckitt Benkiser Group plc, Gepach International, Bliss GVS Pharma Ltd, Thornton & Ross, Ricola AG, Ernest Jackson, Mondelēz International group, GlaxoSmithKline, Pfizer Inc., Doestsch Grether AG are some of the leading companies profiled in MRFR’s report.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/throat-lozenges-market-1212 

Digital Genome Market – Qualitative Insights by 2027

 The global digital genome market share is expected to witness tremendous growth during the forecast period. Digital genome can be used in the diagnosis of rare diseases, genetic diseases, cancer, neurological disorders and others. The rising prevalence of chronic diseases such as breast cancer is driving the market growth. Other essential factors influencing the growth of the market are increasing geriatric population, need for efficient diagnosis and treatment, increasing number of drug discoveries, growing biotech sector, increasing research in the field of genomics and rise in funding related to digitalization. Variants of Presenilin gene lead to Alzheimer’s disease. According to Alzheimer's Association in 2018, 5.7 million people are from Alzheimer’s disease in the Americas. With the help of digital genome identifying genomic variants is easy.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/1125 

However, factors such as high costs of digital genome techniques, lack of knowledge about the digital genome, security issues and inaccurate results are some of the factors expected to hinder the market growth during the forecast period.

Global Digital Genome Market, by Key Players

• Umbel
• BiogeniQ
• GenomeMe
• NanoString
• Illumina, Inc

Segmentation

The global digital genome market is segmented on the basis of product, application, and end-user.  The global digital genome market, by product, is segmented into sequencing services, sequencing instruments, sequencing consumables, bioinformatics and sample preparation kits and reagents. The application segment is segmented into diagnostics, agriculture & animal research, personalized medicine, drug discovery and treatment analysis.  On the basis of end-user, the market is categorized into research centers and government institutes, academic institutions, pharmaceutical & biotechnology industries, hospitals, and diagnostic centers. On the basis of region, the global digital genome market is segmented into the Americas, Europe, Asia-Pacific, and the Middle East and Africa.

The Americas is sub-segmented into North America and South America. The North American region is further segmented into the US and Canada. The European region is divided into two, namely, Western Europe and Eastern Europe. Western Europe is further classified into Germany, Italy, France, the UK, Spain, and the rest of Western Europe. The Asia-Pacific region is sub-segmented into Japan, China, India, Australia, the Republic of Korea, and the rest of Asia-Pacific. The Middle Eastern and African region is sub-segmented into the United Arab Emirates, Saudi Arabia, Oman, Kuwait, Qatar, and the rest of the Middle East and Africa.

Regional Market Summary

The digital genome market is dominated by America owing increasing prevalence of chronic diseases like cancer and diabetes. The Breastcancer.org estimated 266,120 new cases of invasive breast cancer and 63,960 new cases of non-invasive breast cancer in America in 2018. Thus, this provides favorable backgrounds for the market to grow.

It is estimated that Europe stood second in the global digital genome market. The rising demand for personalized medicine and targeted therapy is driving the growth of the market. The European Alliance for Personalized Medicine (EAPM) founded in March 2012, is involved in enhancing patient care for chronic diseases through personalized medicine. According to the European Commission in April 2018, 13 European countries have signed a declaration to share the genomic data to allow personalized treatments against cancer, rare diseases, and neurological diseases.

The digital genome market in Asia-Pacific is expected to witness growth owing to rising diabetes in this region. According to the American Diabetes Association in 2016, the Western Pacific has more than 138.2 million diabetic patients. Also, the rising healthcare spending and growing biotech sector drive the market growth in this region.

The Middle East and Africa holds the least share in the global digital genome market due to low funding in medical and health research. However, the rising prevalence of chronic diseases and increasing healthcare spending favors market growth in this region. According to the Ministry of Finance - KSA (Kingdom of Saudi Arabia) in 2018, 147 billion riyals (USD 39.2 billion) have been allocated for the Health and Social Development Sector. This enhances the market growth of digital genome in this region.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/digital-genome-market-1125 

Cholesterol Management Devices Market 2020 Analysis, Industry Size, Share Leaders, Current Status by Major vendors and Trends by Forecast to 2027

 Cholesterol is a type of lipid molecule, which is biosynthesized by all animal cells as it is an essential structural component of the cells. Cholesterol management devices are used to determine a lipoprotein profile and to measure total cholesterol content, high-density lipoprotein (HOL), low-density lipoprotein (LDL), triglycerides, and other fatty substances found in the human body. The global cholesterol management devices market is driven by increasing obese and overweight population base. According to the World Health Organization (2014), worldwide, more than 1.9 billion adults over 18 years were overweight of which over 600 million were obese. Less physical activity due to the desk-bound nature of many forms of work, changing modes of transportation, government support for the research and development, and increasing urbanization have fueled the growth of the market. However, lack of awareness among the people may slow the growth of the market.

The Global Cholesterol Management Devices Market insights Is Expected To Grow At A CAGR Of 8.5% During The Forecast Period (2017-2023).

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/1045 

Segmentation

The global cholesterol management devices market is segmented on the basis of types, application and end users. On the basis of types, the market is classified into monitors, wrist monitors, small portable instruments, meters, wireless systems, and others. On the basis of applications, the market is categorized into hypercholesterolemia, hypocholesterolemia, cholesterol testing, and others. On the basis of end users, the market is segmented into home based healthcare, hospitals, clinics, and others.

Regional Analysis

America continues to dominate the global cholesterol management devices market owing to the presence of a huge number of people suffering from obesity and overweight. According to the Centers for Disease Control and Prevention (2014), 73.5 million adults in the US had diagnosed with high cholesterol level. Additionally, increasing awareness among the people regarding different monitoring procedures and well-developed technology have also contributed to the growth of the market. Europe is the second largest cholesterol management devices market, which is followed by Asia Pacific. Asia Pacific is the fastest growing region for the market due to the presence of a huge patient population and continuously developing economies. On the other hand, the Middle East & Africa has the least share in the global cholesterol management devices market.

Key Players for Global Cholesterol Management Devices Market

Some of the key player in the market are Boston Scientific Corporation (US), Medtronic (US), St. Jude Medical, LLC. (Canada), Koninklijke Philips N.V. (US), Roche Diagnostics (US), Abbott (US), Alere (US), Sorin Group (Italy), BIOTRONIK SE & Co. KG (Germany), Bio-AMD (UK) and others.

The report for the global cholesterol management devices market of Market Research Future comprises of extensive primary research along with the detailed analysis of qualitative as well as quantitative aspects by various industry experts, key opinion leaders to gain the deeper insight of the market and industry performance. The report gives a clear picture of the current market scenario which includes historical and projected market size in terms of value and volume, technological advancement, macro economical and governing factors in the market. The report provides details information and strategies of the top key players in the industry. The report also gives a broad study of the different markets segments and regions.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/cholesterol-management-devices-market-1045 

CPAP Devices Market 2020 Analysis, Industry Size, Share Leaders, Current Status by Major vendors and Trends by Forecast to 2027

 Continuous positive airway pressure (CPAP) devices are used in the treatment of choice for obstructive sleep apnea syndrome. CPAP works by blowing air into the nose and throat. The blow causes a positive pressure to hold the upper airway open during sleep and thus helps in the treatment of snoring. This device typically used when the patient has a breathing problem. Additionally, it increases the air pressure in the throat to avoid airway from collapsing when breathing. It can be used every night at home while sleeping. The global CPAP market is majorly driven by increasing number of patients with sleep apnea, obesity, and other respiratory diseases. According to the World Health Organization (WHO), in 2016, more than 1.9 billion adults, above 18 years were overweight. Out of these over 650 million were obese. The report also suggests that over 340 million children and adolescents aged 5-19 were overweight or obese in 2016. Thus, rising number of patient with obesity generating the exponential demand for CPAP devices market.

Browse Sample of the Report @  https://www.marketresearchfuture.com/sample_request/939 

According to the WHO, in 2016, around 39% of 41 million children under the age of 5 were overweight or obese. Advances in technology such as improved mask design, oral appliances, use of oxygen devices, rising healthcare expenditure, and increasing demand for the devices have fuelled the market growth. However, CPAP is not always effective since some patients find it uncomfortable and sometimes it shows adverse effects. The high cost of the devices and their adverse effect may slow the market growth.

Global continuous positive airway pressure (CPAP) devices market is expected to grow at a CAGR of 7.1% during the forecast period 2017-2027. 

Segmentations

Global continuous positive airway pressure (CPAP) devices market is segmented on the basis of product type, features, automation, and end user

On the basis of the product type, it is segmented into CPAP motors, CPAP hoses, CPAP mask, and others.

On the basis of the features, it is segmented into the humidifier, portability, heated tubing, and others.

On the basis of the automation, it is segmented into manual and automatic.

On the basis of the end user, it is segmented into hospitals, private clinics, home care, and others.

Regional Analysis

The Americas hold the largest share of the global market owing to increasing incidence of obesity, unhealthy diet, and physical inactivity. According to the updated report by the Centers for Disease Control and Prevention (CDC) in 2017, a total number of adults diagnosed with chronic bronchitis in the past year was 9.3 million. The report further adds that around 3.8% of the total adult population in the U.S. diagnosed with chronic bronchitis, in 2016. Presence of well-developed technology, high health care spending, increased R&D activities, and the concentration of major companies have fuelled the growth of the market in this region.

Europe holds the second position followed by the Asia Pacific in the global CPAP devices market owing to the rising patient population diagnosed with respiratory diseases. Furthermore, the government support for research & development and availability of funds for research are likely to fuel the CPAP devices market growth over the forecast period.

Asia Pacific is the fastest growing CPAP devices market owing to unhealthy diet and associated lifestyle changes. Moreover, the increased presence of rapidly developing healthcare technology, high healthcare expenditure, R&D activities, and the concentration of major companies are fuelling the growth of the market in this region. Increasing demand for new treatment methods in countries like India and South Korea is likely to emerge as the fastest growing market across the globe.

On the other hand, the Middle East and Africa account for the lowest share of the global market owing to lack of technical knowledge and poor medical facilities. 

Key Players

Some of key the players in the market are Medtronic (U.S.), Koninklijke Philips N.V. (the Netherlands), 3B Medical, Inc. (U.S.), Armstrong Medical Inc. (U.S.), ResMed (U.S.), Smiths Medical (U.S.), Apex Medical Corp. (Taiwan), Fisher & Phillips LLP (U.S.), Cardinal Health (U.S.) Beijing Dehaier Medical Technology Co., Ltd. (China), DeVilbiss Healthcare LLC (US), and Invacare Corporation (US).

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/continuous-positive-airway-pressure-devices-market-939 

About US:

 

Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact Us:

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune – 411028

Maharashtra, India

Phone: +1 646 845 9312

Email: sales@marketresearchfuture.com